Table 1 Baseline characteristics of the 19 patients with HER2-positive breast cancer who showed normal (N) or reduced (R) left ventricular ejection fraction
Group N (n = 10) | Group R (n = 9) | p-value | |
|---|---|---|---|
Age (yrs) | 49 ± 7 | 57 ± 9 | 0.071 |
Body mass index (kg/m2) | 22 ± 2 | 25 ± 3 | 0.037 |
Cardiovascular risk factors | |||
Hypertension | 1 (10%) | 1 (11%) | 0.941 |
Diabetes | 0 (0%) | 0 (0%) | |
Hyperlipidemia | 2 (20%) | 2 (22%) | 0.912 |
Smoking | 2 (20%) | 4 (44%) | 0.277 |
Family history of CAD | 1 (10%) | 0 (0%) | 0.357 |
Side of breast cancer | |||
Right | 6 (60%) | 8 (89%) | 0.171 |
Left | 4 (40%) | 1 (11%) | |
Bilateral | 0 (0%) | 0 (0%) | |
Radiation | 7 (70%) | 5 (56%) | 0.541 |
Chemotherapy | |||
Doxorubicin 240 mg/m2 | 1 (10%) | 4 (44%) | 0.098 |
Epirubicin 300 mg/m2 | 9 (90%) | 5 (56%) | |
Creatinine (mg/dL) | 0.55 ± 0.10 | 0.50 ± 0.07 | 0.225 |
eGFR (mL/min/1.73 m2) | 93.9 ± 19.0 | 100.5 ± 21.1 | 0.509 |
Echocardiographic parameters | |||
LVEF (%) | 68 ± 5 | 71 ± 3 | 0.103 |
LVDd (mm) | 44 ± 3 | 44 ± 4 | 0.756 |
E/A | 1.44 ± 0.41 | 1.00 ± 0.36 | 0.028 |
DcT (ms) | 185 ± 26 | 227 ± 48 | 0.040 |
e’ (cm/s) | 11.2 ± 3.2 | 7.6 ± 2.0 | 0.019 |